Eloisa Riva
Overview
Explore the profile of Eloisa Riva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naiki H, Johnson M, Walters K, Carpinteiro A, Cibeira M, DSouza A, et al.
Amyloid
. 2025 Feb;
:1-6.
PMID: 39928315
Background: Accurate tissue typing in amyloidosis is essential to provide appropriate therapy for individual patients. Objective: To get a real-life overview of typing strategies worldwide. Methods: The International Society of...
2.
Garderet L, Gras L, Koster L, Baaij L, Hamad N, DSouza A, et al.
Am J Hematol
. 2024 Aug;
99(11):2084-2095.
PMID: 39158218
Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and...
3.
Gallardo-Perez M, Negrete-Rodriguez P, Gertz M, Pena C, Riva E, Gilli V, et al.
Acta Haematol
. 2024 Aug;
:1-9.
PMID: 39128463
Introduction: POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The acronym refers to the following features: polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal paraproteinemia, and skin changes....
4.
Basset M, Schonland S, Obici L, Gunther J, Riva E, Dittrich T, et al.
J Am Soc Nephrol
. 2024 Mar;
35(6):782-794.
PMID: 38512269
No abstract available.
5.
Garrido D, Bove V, Villano F, Riva E
Acta Medica (Hradec Kralove)
. 2024 Mar;
66(3):117-121.
PMID: 38511422
Introduction: Autologous stem cell transplantation (ASCT) is the standard consolidation option for transplant-eligible patients with multiple myeloma (MM). The aim of this study is to report the overall survival (OS)...
6.
Riva E, Garrido D, Villano F, Bove V
Hematol Transfus Cell Ther
. 2024 Feb;
46(4):434-442.
PMID: 38307822
Introduction: Infections represent a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in newly diagnosed MM (NDMM) patients are...
7.
Martinez-Cordero H, Pena C, Schutz N, Bove V, Villano F, Beltran C, et al.
JCO Glob Oncol
. 2023 Dec;
9:e2300182.
PMID: 38060975
Purpose: Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce....
8.
Riva E, Hungria V, Chiattone C, Martinez-Cordero H
Hematol Oncol Clin North Am
. 2023 May;
37(4):801-807.
PMID: 37258356
Waldenström macroglobulinemia (WM) is a rare, indolent, and currently incurable B-cell neoplasm characterized by monoclonal immunoglobulin M gammopathy, frequent nodal involvement, and lymphoplasmacytic infiltration of the bone marrow. The clinical...
9.
Pena C, Riva E, Schutz N, Ramirez A, Vasquez J, Del Carpio D, et al.
Leuk Lymphoma
. 2023 Jan;
64(4):816-821.
PMID: 36695519
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric,...
10.
Garrido D, Slavutsky I, Riva E
Curr Probl Cancer
. 2022 Dec;
47(1):100916.
PMID: 36473780
Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This...